This database contains 457 studies, archived under the term: "drug therapy"
Click here to filter this large number of results.
Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
Siemers, Eric R.,
Friedrich, Stuart,
Dean, Robert A.,
Gonzales, Celedon R.,
Farlow, Martin R.,
Paul, Steven M.,
Demattos, Ronald B.
Objectives: Active and passive immunization strategies have been suggested as possible options for the treatment of Alzheimer disease (AD). LY2062430 (solanezumab) is a humanized monoclonal antibody being studied as a putative disease-modifying treatment of AD.; Methods: Patients with mild to moderate AD were screened and selected for inclusion. Initial screening was performed for 54 subjects, […]
Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease
Blesa González, R.,
Boada Rovira, M.,
Martínez Parra, C.,
Gil-Saladié, D.,
Almagro, C. A.,
Gobartt Vázquez, A. L.
Introduction: Rivastigmine transdermal patches for the treatment of Alzheimer’s disease (AD) have potential benefits compared to capsules because of their sustained absorption through the skin, good local tolerability and reduction of gastrointestinal problems.; Purpose: To assess gastrointestinal and skin tolerability and the need for optimal dose titration of rivastigmine transdermal patches in Alzheimer’s disease patients […]
A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease
Objectives: To evaluate the safety of the peroxisome proliferator-activated receptor gamma agonist pioglitazone in nondiabetic patients with Alzheimer disease (AD) and to explore treatment effect sizes on clinical outcomes.; Design: Double-blind, placebo-controlled randomized controlled trial of 18-month duration.; Setting: Two academic medical center outpatient clinics.; Patients: Nondiabetic patients meeting research criteria for probable AD were […]
Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer’s disease
Maher-Edwards, G.,
Zvartau-Hind, M.,
Hunter, A. J.,
Gold, M.,
Hopton, G.,
Jacobs, G.,
Davy, M.,
Williams, P.
Background: This randomized, double-blind, placebo-controlled study investigated the efficacy and tolerability of the 5-HT6 receptor antagonist, SB-742457, in subjects with mild-to-moderate probable Alzheimer’s disease (AD).; Methods: Participating subjects had a Mini-Mental State Examination (MMSE) score of 12 to 26 after a 4-week, single-blind, placebo run-in phase, and were randomized (2:1:1:2) to receive placebo, SB-742457 5 […]
Effect of memantine on resting state default mode network activity in Alzheimer’s disease
Lorenzi, Marco,
Beltramello, Alberto,
Mercuri, Nicola B.,
Canu, Elisa,
Zoccatelli, Giada,
Pizzini, Francesca B.,
Alessandrini, Franco,
Cotelli, Maria,
Rosini, Sandra,
Costardi, Daniela,
Caltagirone, Carlo,
Frisoni, Giovanni B.
Background: Memantine is an approved symptomatic treatment for moderate to severe Alzheimer’s disease that reduces the excitotoxic effects of hyperactive glutamatergic transmission. However, the exact mechanism of the effect of memantine in Alzheimer’s disease patients is poorly understood. Importantly, the default mode network (DMN), which plays a key role in attention, is hypoactive in Alzheimer’s […]
A multi-center randomized proof-of-concept clinical trial applying ¹⁸FFDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer’s disease
Tzimopoulou, Sofia,
Cunningham, Vincent J.,
Nichols, Thomas E.,
Searle, Graham,
Bird, Nick P.,
Mistry, Prafull,
Dixon, Ian J.,
Hallett, William A.,
Whitcher, Brandon,
Brown, Andrew P.,
Zvartau-Hind, Marina,
Lotay, Narinder,
Lai, Robert Y. K.,
Castiglia, Mary,
Jeter, Barbara,
Matthews, Julian C.,
Chen, Kewei,
Bandy, Dan,
Reiman, Eric M.,
Gold, Michael,
Rabiner, Eugenii A.,
Matthews, Paul M.
Here we report the first multi-center clinical trial in Alzheimer’s disease (AD) using fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) measures of brain glucose metabolism as the primary outcome. We contrasted effects of 12 months treatment with the PPARγ agonist Rosiglitazone XR versus placebo in 80 mild to moderate AD patients. Secondary objectives included testing for reduction […]
Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer’s disease
Straten, Guido,
Saur, Ralf,
Laske, Christoph,
Gasser, Thomas,
Annas, Peter,
Basun, Hans,
Leyhe, Thomas
Preclinical and clinical studies gave evidence that lithium could be useful in the treatment of Alzheimer’s disease (AD). One possible mechanism of action might be the induction of neurotrophins. Recently, we found a significant increase of brain-derived neurotrophic factor (BDNF) serum levels in AD patients treated with lithium and a significant decrease of ADAS Cog […]
Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers
Serrano-Pozo, Alberto,
Vega, Gloria L.,
Lütjohann, Dieter,
Locascio, Joseph J.,
Tennis, Marsha K.,
Deng, Amy,
Atri, Alireza,
Hyman, Bradley T.,
Irizarry, Michael C.,
Growdon, John H.
Preclinical and epidemiologic studies suggest a protective effect of statins on Alzheimer disease (AD). Experimental evidence indicates that some statins can cross the blood-brain barrier, alter brain cholesterol metabolism, and may ultimately decrease the production of amyloid-beta (Abeta) peptide. Despite these promising leads, clinical trials have yielded inconsistent results regarding the benefits of statin treatment […]